JP2019529476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529476A5 JP2019529476A5 JP2019516536A JP2019516536A JP2019529476A5 JP 2019529476 A5 JP2019529476 A5 JP 2019529476A5 JP 2019516536 A JP2019516536 A JP 2019516536A JP 2019516536 A JP2019516536 A JP 2019516536A JP 2019529476 A5 JP2019529476 A5 JP 2019529476A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cabozantinib
- urinary tract
- cell carcinoma
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400481P | 2016-09-27 | 2016-09-27 | |
| US62/400,481 | 2016-09-27 | ||
| US201762457952P | 2017-02-12 | 2017-02-12 | |
| US62/457,952 | 2017-02-12 | ||
| US201762459340P | 2017-02-15 | 2017-02-15 | |
| US62/459,340 | 2017-02-15 | ||
| US201762552296P | 2017-08-30 | 2017-08-30 | |
| US62/552,296 | 2017-08-30 | ||
| PCT/US2017/053766 WO2018064191A1 (en) | 2016-09-27 | 2017-09-27 | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529476A JP2019529476A (ja) | 2019-10-17 |
| JP2019529476A5 true JP2019529476A5 (enExample) | 2020-11-12 |
Family
ID=60190916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516536A Withdrawn JP2019529476A (ja) | 2016-09-27 | 2017-09-27 | Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210275515A1 (enExample) |
| EP (1) | EP3518928A1 (enExample) |
| JP (1) | JP2019529476A (enExample) |
| AU (1) | AU2017336547A1 (enExample) |
| CA (1) | CA3038500A1 (enExample) |
| MA (1) | MA46355A (enExample) |
| WO (1) | WO2018064191A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201837467A (zh) | 2017-03-01 | 2018-10-16 | 美商建南德克公司 | 用於癌症之診斷及治療方法 |
| CN117402114A (zh) | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| TWI831259B (zh) | 2018-06-15 | 2024-02-01 | 漢達生技醫藥股份有限公司 | 包含達沙替尼十二烷基硫酸鹽組合物的膠囊 |
| EP3867646A1 (en) * | 2018-10-18 | 2021-08-25 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
| IL300151A (en) * | 2020-07-31 | 2023-03-01 | Exelixis Inc | Combinations for cancer treatment |
| CA3202761A1 (en) * | 2020-11-25 | 2022-06-02 | Nanocopoeia, Llc | Amorphous cabozantinib particles and uses thereof |
| US11590122B2 (en) | 2021-02-19 | 2023-02-28 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
| US20220362235A1 (en) * | 2021-02-19 | 2022-11-17 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
| US20220280500A1 (en) * | 2021-02-19 | 2022-09-08 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
| US20220387418A1 (en) * | 2021-02-19 | 2022-12-08 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
| WO2024163400A1 (en) | 2023-01-31 | 2024-08-08 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| US20080200515A1 (en) | 2006-12-29 | 2008-08-21 | Tap Pharmaceutical Products Inc. | Solid state forms of enantiopure ilaprazole |
| EA030435B1 (ru) | 2010-07-16 | 2018-08-31 | Экселиксис, Инк. | ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ |
| BR112013020362A2 (pt) | 2011-02-10 | 2018-05-29 | Exelixis Inc | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem |
-
2017
- 2017-09-27 WO PCT/US2017/053766 patent/WO2018064191A1/en not_active Ceased
- 2017-09-27 CA CA3038500A patent/CA3038500A1/en not_active Abandoned
- 2017-09-27 US US16/336,724 patent/US20210275515A1/en not_active Abandoned
- 2017-09-27 AU AU2017336547A patent/AU2017336547A1/en not_active Abandoned
- 2017-09-27 EP EP17791484.3A patent/EP3518928A1/en not_active Withdrawn
- 2017-09-27 JP JP2019516536A patent/JP2019529476A/ja not_active Withdrawn
- 2017-09-27 MA MA046355A patent/MA46355A/fr unknown
-
2022
- 2022-11-29 US US18/059,840 patent/US20230130243A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529476A5 (enExample) | ||
| JP2022022264A5 (enExample) | ||
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2017039771A5 (enExample) | ||
| JP2022533578A5 (enExample) | ||
| EP4178573A1 (en) | Combination therapy for treating abnormal cell growth | |
| JP2015534579A5 (enExample) | ||
| CN118103040A (zh) | 用于治疗异常细胞生长的组合疗法 | |
| JP2022542238A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| CN101669941B (zh) | 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物 | |
| CN108778332B (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| JP2021502415A (ja) | 癌の処置のためのアパチニブを用いる併用療法 | |
| JP2012531430A5 (enExample) | ||
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| JP2022523530A5 (enExample) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP2012525358A5 (enExample) | ||
| CN109663145A (zh) | 一种碘油靶向药物复合物 | |
| AU2016294332A1 (en) | Treatment of pruritus | |
| JP2024506385A5 (enExample) | ||
| Alfonso et al. | Previous gastric bypass surgery complicating total thyroidectomy. | |
| JP2020512292A5 (enExample) | ||
| US11458104B1 (en) | Enteric coated tiopronin tablet |